Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 4, 2009, Pages 875-877

  Tong, C Y William ^a,b   Mullen, Jane E ^a   Wong, Terry ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Baseline resistance; Early onset virological failure; Treatment naive

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; LETTER; MALE; REBOUND; VIRUS LOAD;

ADULT; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B; HUMANS; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; SELECTION, GENETIC; TREATMENT OUTCOME;

EID: 70349440589     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp283     Document Type: Letter

References (6)

1. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
2. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
3. Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-14.
4. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009; 50: 227-42.
5. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
6. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.